Dr Lalchandani Labs share price
BSE: 541299Healthcare ServicesSmall Cap
DR LALCHANDANI LABS LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2018
Last close ₹6.95down ₹0.12 (1.70%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹7.07.
29 Oct: open ₹7.47, high ₹7.47, low ₹6.37
52-week range of traded prices to 29 Oct 2026
₹5.81Low, 9 Oct 2026₹23.69High, 12 Jan 2026
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6.00 Cr4,613th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 94.53
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 40,000
Results
Standalone; ₹ crore.Dr Lalchandani Labs half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −6.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −84.8%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹2.13 Crup 4.08%
- Net profitNet profit. Under it, net profit in the half year before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹0.13 CrHalf year to Sep 2025: ₹0.20 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −6.2%
Revenue by half year
Peak revenue ₹2.76 Cr, half year to Mar 2023; lowest ₹2.05 Cr, half year to Sep 2025
Net profit by half year, a loss in red
- Net profit
- Loss
A loss in the half year to Mar 2026, −₹0.13 CrA loss in 4 of the 7 half years shown
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.28 | 2.76 | 2.73 | 2.13 | 2.33 | 2.05 | 2.13 |
| Net profit | −0.97 | −0.59 | −0.09 | 0.15 | 0.27 | 0.20 | −0.13 |
| Net margin | −42.6% | −21.4% | −3.2% | 7.1% | 11.4% | 9.5% | −6.2% |
Standalone. The last eight half years, but for those filed as quarters, which are below. The latest is shaded.
| ₹ crore | Mar 2024 |
|---|---|
| Revenue | 2.08 |
| Net profit | 0.71 |
| Net margin | 33.9% |
Standalone. The quarters the company also filed in the same span.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4.19 Crdown 6.02%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹0.06 Crdown 84.76%
- Net margin
- 1.5%
Revenue by year
Peak revenue ₹11 Cr, year to Mar 2022; lowest ₹4.19 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 9 years shown
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.9 | 5.3 | 6.1 | 9.8 | 11.3 | 5.0 | 4.8 | 4.5 | 4.2 |
| Net profit | 0.8 | 0.5 | 0.5 | 1.0 | 0.9 | −1.6 | 0.6 | 0.4 | 0.1 |
| Net margin | 16.7% | 10.1% | 7.8% | 10.3% | 8.3% | −31.0% | 12.8% | 9.4% | 1.5% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Healthcare, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +44.9% | −92.3% | +1,793.9% | 0.0% |
| 3 years | −19.5% | – | – | 0.0% |
| 5 years | +1.3% | −49.9% | +102.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Dr Lalchandani Labs insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 3 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Dr Lalchandani Labs competitors and peers
Healthcare Service Provider, 37 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Dr Lalchandani Labs in market cap. 3 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Dolphin Medical ServicesDOLPHMED | 10 | – | 1.02 | – | – | – | – | 0.00% |
 Family Care HospitalsFAMILYCARE | 10 | – | 1.05 | −93.9% | – | −73.4% | −27.5% | 0.00% |
 Dhanvantri Jeevan RekhaZDHJERK | 9 | – | 0.86 | +49.9% | – | – | 1.9% | 0.00% |
 Looks Health ServicesLOOKS | 8 | 334.69 | 0.54 | −5.1% | −69.0% | 0.2% | 0.2% | 0.00% |
 Boston Commerce531458 | 8 | – | – | – | – | – | – | 0.00% |
 Clinitech LaboratoryCTLLAB | 7 | 16.85 | 0.76 | – | – | 4.6% | – | 0.00% |
 Ashram Online.comASHRAM | 5 | – | 0.49 | +26.0% | – | −1.0% | −2.7% | 0.00% |
 Gian Life CareGIANLIFE | 4 | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Dr Lalchandani Labs announcements
Sep 2026
Jun 2026
May 2026
30 May · Announcement under Regulation 30 (LODR)-Meeting Updates
28 May · Opening Of New Centre At Dwarka Delhi
27 May · Board meeting
Meeting on 30 May 2026: audited results
Dr Lalchandani Labs share price by year
Each calendar year to 2025.Dr Lalchandani Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 20.81 | +23.1% | 27.35 | 10.22 |
| 2024 | 16.90 | −20.4% | 27.60 | 15.68 |
| 2023 | 21.23 | −22.8% | 35.00 | 19.80 |
| 2022 | 27.50 | −32.5% | 44.50 | 18.80 |
| 2021 | 40.75 | +198.5% | 49.65 | 10.80 |
| 2020 | 13.65 | +17.7% | 16.70 | 8.11 |
| 2019 | 11.60 | −47.9% | 23.85 | 10.40 |
| 2018 | 22.25 | – | 31.05 | 21.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 9 May 2018. The 2018 close is its last trade, on 7 Dec 2018.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 6.99 | 7.07 | 6.99 | 7.07 | 7.04 | 16,000 |
| 27 Oct 2026 | 6.89 | 7.62 | 6.89 | 7.26 | 7.25 | 8,000 |
| 23 Oct 2026 | 6.63 | 6.96 | 6.61 | 6.96 | 6.65 | 44,000 |
| 21 Oct 2026 | 7.42 | 7.42 | 6.81 | 7.15 | 7.13 | 12,000 |
| 19 Oct 2026 | 6.78 | 7.67 | 6.30 | 7.49 | 6.71 | 72,000 |
| 16 Oct 2026 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 8,000 |
| 15 Oct 2026 | 7.29 | 7.29 | 6.80 | 7.14 | 6.97 | 28,000 |
| 14 Oct 2026 | 7.69 | 7.69 | 6.80 | 7.29 | 6.97 | 60,000 |
| 13 Oct 2026 | 6.03 | 7.12 | 6.03 | 7.00 | 6.53 | 60,000 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 27 Jan 2026 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 27 Jan 2026 | Price move | – | A corporate action went ex within three days of this move (Right Issue of Equity Shares, ex-date 27 Jan 2026), and its terms do not account for the move. Not adjusted for. |
| 8 Dec 2023 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 16 Aug 2022 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 25 May 2022 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
Each event is noted and not adjusted for.
Company details
- BSE code
- 541299
- ISIN
- INE871Z01013
- Industry
- Healthcare Services
- Website
- www.lalchandanipathlab.com
- CIN
- L85320DL2017PLC321605
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2017
- Registered office
- M-20 Basement, Greater Kailash-1, New Delhi 110048, Delhi
- Share registrar
- Cameo Corporate Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments